International Clinical Trial: A phase II open-label, randomized controlled study of lenvatinib combined with pembrolizumab, with or without branched-chain amino acid combination therapy, for unresectable hepatocellular carcinoma

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127139) titled 'A phase II open-label, randomized controlled study of lenvatinib combined with pembrolizumab, with or without branched-chain amino acid combination therapy, for unresectable hepatocellular carcinoma' on June 25.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Huashan Hospital, Fudan University

Condition: Unresectable hepatocellular carcinoma.

Intervention: Lenvatinib + Pembrolizumab + Branched-Chain Amino Acids (BCAA) group:Lenvatinib + Pembrolizumab + Branched-Chain Amino Acids (BCAA)

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-06-30

Target Sam...